CLL Coverage from Every Angle

Jennifer R. Brown, MD, PhD, on Treating CLL With the Novel Immunotherapy KTE-X19

Posted: Tuesday, September 3, 2019

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, describes the immunotherapy KTE-X19, its proposed mechanism in relapsed or refractory chronic lymphocytic leukemia, and how it might be incorporated into a therapeutic plan.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.